Toronto, Ontario — December 8, 2025 — Leads & Copy — Predictmedix AI Inc. (CSE: PMED) (OTC Pink: PMEDF) (FSE: 3QP0) has closed the final tranche of its non-brokered private placement, raising total capital of $612,650 across all tranches.
The final tranche involved the issuance of 3,050,000 units at $0.05 per unit, yielding gross proceeds of $152,500. Each unit includes one common share of Predictmedix and one-half of a common share purchase warrant. A warrant entitles the holder to purchase one-half common share of the company at C$0.15 for 36 months after the offering’s closing date.
According to the company, if, four months after the closing date, the volume weighted average price of common shares on the CSE equals or exceeds $0.30 for 10 consecutive trading days, Predictmedix can expedite the warrant expiry date to 30 days following written notice to warrant holders.
Dr. Rahul Kushwah, COO of Predictmedix AI, said the company opted to accept a reduced amount to maintain share-structure integrity and avoid unnecessary dilution for long-term investors. Kushwah added that the priority was to welcome investors who bring meaningful strategic contributions through their expertise and networks, rather than simply maximizing capital.
All securities issued during the private placement are subject to a four-month statutory hold period from the issuance date.
Predictmedix AI Inc. is a provider of health screening and remote patient care solutions. Its Smarthealth AI stations use multispectral cameras to analyze physiological data patterns and predict health issues, including vital parameters, impairment, fatigue, and mental illnesses. The company’s remote patient care platform provides medical professionals with AI-powered tools to improve patient outcomes.
Details of the company’s recent product validations, pilot programs, and strategic partnerships can be found in earlier press releases available at: https://predictmedix.com/press-releases/
Dr. Rahul Kushwah, COO
rahul@predictmedix.com
(647) 889 6916
Caution Regarding Forward-Looking Information:This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results of the Company. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances. The Company’s securities have not been registered under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”), or applicable state securities laws, and may not be offered or sold to, or for the account or benefit of, persons in the United States or “U.S. Persons”, as such term is defined in Regulations under the U.S. Securities Act, absent registration or an applicable exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or any jurisdiction in which such offer, solicitation or sale would be unlawful. Additionally, there are known and unknown risk factors which could cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein, such as, but not limited to dependence on obtaining regulatory approvals; the ability to obtain intellectual property rights related to its technology; limited operating history; general business, economic, competitive, political, regulatory and social uncertainties, and in particular, uncertainties related to COVID-19; risks related to factors beyond the control of the Company, including risks related to COVID-19; risks related to the Company’s shares, including price volatility due to events that may or may not be within such party’s control; reliance on management; and the emergency of additional competitors in the industry.
All forward-looking information herein is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except required by law.
Disclaimer: The Company is not making any express or implied claims that its product has the ability to diagnose, eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus) at this time.
THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED NOR DOES IT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
